Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study

MARCO SCALA, PAOLA MEREU, FRANCESCO SPAGNOLO, MICHELA MASSA, ANNALISA BARLA, SOFIA MOSCI, GILBERTO FORNO, ANDRA INGENITO and PAOLO STRADA
In Vivo January 2014, 28 (1) 121-124;
MARCO SCALA
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAOLA MEREU
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO SPAGNOLO
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: francesco.spagnolo85{at}gmail.com
MICHELA MASSA
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNALISA BARLA
2Department of Computer and Information Science, University of Genova, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOFIA MOSCI
2Department of Computer and Information Science, University of Genova, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GILBERTO FORNO
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDRA INGENITO
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAOLO STRADA
1IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Salivary gland tumors are mostly benign tumors. Whether a more conservative surgical approach at greater risk of recurrence, or a more radical intervention with an increased risk of facial paralysis is warranted is still under discussion. Our study addresses the opportunity for improving surgical outcome by employing platelet-rich plasma (PRP) gel at the surgical site. Patients and Methods: Twenty consecutive patients undergoing superficial parotidectomy were randomized and assigned to two groups, one with and one without PRP gel. Many parameters were evaluated after surgery and during follow-up, such as the duration of hospitalization, facial nerve deficit, onset of Frey's syndrome, relapse, cosmetic results, presence of keloid or scar depressions, behavior of several facial muscles. Results: Our explorative analysis suggests a positive effect of PRP on surgical outcome in patients undergoing parotidectomy, whereas no negative effects were detected. Conclusion: This work suggests that administration of PRP in patients undergoing parotidectomy is beneficial.

  • Regenerative medicine
  • platelet-rich plasma
  • platelet gel
  • parotidectomy
  • salivary gland tumors

Salivary gland tumors (SGT) are mostly (80-90%) benign tumors with heterogeneous histopathology and great variety in their evolution. These tumors are uncommon, representing fewer than 3% of all head and neck tumors. The most frequent SGT is pleomorphic adenoma, representing 60-70% of all parotid gland tumors (1, 2); other SGTs are monomorphic adenomas (cysto-adeno lymphoma or Warthin tumor, oncocytomas, monomorphic adenomas) and epithelial tumors. The parotid is by far the most affected salivary gland (3).

Specific anatomic configuration, as well as structures involved in the tumor site and histology defines the optimal therapeutic plan; for instance, pleomorphic adenoma tends to grow locally with ramifications and neoplastic satellitosis, with a percentage of approximately 3% to 6% malignant progression. Simple enucleation or enucleoresection are considered inadequate because of a recurrence rate of more than 10% (4), tumor rupture, local dissemination of tumor cells and frequent positive resection margins. A radical approach with facial nerve preservation could be more appropriate.

However, it is still under discussion whether a more conservative approach should be followed, with greater risk of recurrence and an increased incidence of Frey's syndrome, or a more radical intervention such as total parotidectomy should be employed, with an increased risk of facial paralysis. Recent studies on superficial adenomas have shown that adopting a more conservative approach leads to fewer side-effects on the facial nerve and a comparable lower incidence of relapse (5).

Impaired postoperative facial nerve function, whether persistent or temporary, represents a substantial negative impact on the quality of life (6). It is a frequent side-effect of total parotidectomy, while in superficial parotidectomy its incidence is very low (5, 7). If the nerve itself is not interrupted (8), nervous function will recover in about three months; such reliable and more conservative approaches provide good long-term results (5).

Our study addresses the opportunity of consistently improving the surgical outcome, speeding-up the healing process and enhancing cosmetic results by employing a platelet-rich plasma (PRP) gel at the surgical site. It focuses on the possibility of reducing temporary paralysis of the facial nerve after surgery and ameliorating sensitivity of the cutaneus region innervated by the great auricular nerve. In recent literature, PRP combined with epineural or perineural suture was reported to improve re-myelination of the interrupted sciatic nerve (9). This interesting finding provides a intriguing perspective for future studies on the effect of PRP on diseases of the nervous system.

Regenerative surgery can repair and regenerate tissues by using natural components able to recruit and proliferate progenitor cells involved in tissue regeneration. Recent advances in modern transfusion medicine have allowed regenerative surgery to adopt a new set of products and technologies, such as fibrin glue and PRP gel, that allow for improved surgical outcomes and shorter healing. In particular, PRP gel can be applied where loss of substance has occurred, filling cavities and, at the same time, stimulating tissue regeneration by the action of growth factors contained in the platelet alpha granules (10). Indeed, growth factors seem to play a crucial role in the healing process, as it was shown that the initial phase of tissue repair is triggered by platelet de-granulation when platelets aggregate. In this process, several growth factors are released which possess strong recruiting and proliferating actions: PDGF, TGF-β, IGF-I and II and VEGF (11).

In particular, TGF-β induces a chemotactic action on neutrophils and monocytes, PDGF drives the recruitment of fibroblasts and matrix remodeling, and VEGF (a permeability vascular factor) influences plasma protein extravasation in order to support epithelial and endothelial cells. Dermal fibroblasts also play an important role in tissue remodeling and wound healing (12). The literature shows improved healing as compared to standard treatments, due to autologous platelet-derived wound-healing factors, which regulate wound healing of chronic cutaneous ulcers by promoting formation of granulation tissue in the early healing phase (13).

Currently, the use of PRP is widespread in dentistry and maxillofacial surgery for implantation and bone regeneration, and is largely expanding in bone surgery (14, 15). In this series we address the role of PRP in wound healing process, in preserving facial nerve functionality and improving post-surgical cosmetic results.

Patients and Methods

Patient enrollment. From November 2005 to August 2009, 20 consecutive patients with benign parotid gland tumor referred to the National Institute for Cancer Research in Genoa were recruited in the study. Our experimental protocol was approved by the Ethical Committee of our Insitute according to the precepts established by the Helsinki Declaration.

All patients with parotid gland mixed tumor were screened for the study: patients were considered eligible if suitable for surgery and if they agreed to undergo pre- and post-operative rehabilitation visits; patients were considered ineligible if they had previous neurological deficiencies of facial muscles or if they had a previous malignancy (excluding basal cell carcinoma) within five years from randomization. Eligible patients were randomized and assigned to one of two groups. In the first group, patients underwent surgery with regenerative PRP, while in the second group PRP was not applied. All patients enrolled in the study underwent diagnostic tests including ultrasound of the parotid lodge and cytological examination, while other additional investigations such as CT scans or MRI were performed only when there was a suspicion of a malignant neoplasia revealed either by cytology or by the involvement of parapharyngeal area or deeper lobe, shown by echography. The indication for surgery was based on the diagnostic findings. During follow-up many parameters were evaluated: facial nerve deficit, onset of Frey's syndrome, time for a full recovery of facial muscles functionality, relapse (by U.S. examination), cosmetic results, presence of keloid/depressions, behavior of several facial muscles (buccinator, corrugator supercilii, frontalis, great auricular, mentalis, orbicularis oris, orbicularis oculi, platisma, zygomaticus).

In our study, all patients were affected by a mixed tumor of the parotid gland and underwent superficial parotidectomy surgery.

PRP preparation. PRP was procured by collecting a standard unit of blood (450 ml±10%), usually two days before surgery. Red blood cells were re-infused to the patient, while the PRP was separated into platelet-poor plasma (PPP) and platelet concentrate (PC). PPP was immediately frozen at −80°C, while PC was stored at +22°C under continuous agitation. After freezing, PPP was placed at +4°C overnight with the satellite bag attached, and the cryoprecipitate was prepared.

Autologous thrombin was prepared starting from 20 ml of blood collected in two sterile tubes. The tube was maintained for 2 h at 37° and then was centrifuged at 3,000 rpm for 20 min. The thrombin was transferred to a second sterile tube and stored at −30°C until use.

Quality assessments performed on the final products were required to indicate the presence of the following components in at least 75% of the preparation: absolute platelet count: 60×109/μl, residual leukocytes: 0.2×109/μl, quantity: 40 ml, cryoprecipitate: factor VII: 70 IU; fibrinogen: 140 mg/unit.

The quantity of PRP was standardized (22 ml). Preparation was performed under sterile condition: 10 ml of PC and cryoprecipitate were put in one or more Petri dishes; 1 ml of autologous thrombin and 1 ml of calcium gluconate were added and mixed with a sterile pipette for a few seconds. The product was used within 8 h after delivery and was stored at room temperature until use. PRP gel was applied to the excision site and placed around nerves endings.

Statistical analysis. In order to better-evaluate the potential effects of PRP gel use, we performed a t-test (16) for each measured clinical parameter. The main aim was to identify the parameters that are significantly altered in patients to whom PRP was applied, with respect to patients that did not undergo gel application. We considered as relevant those parameters associated with a p-value less than 0.1.

Results

The two groups were homogeneous for male/female ratio (p=0.84) and age (p=0.60). The median age for the PRP group was 46 years (range=24-55), while that for the other group was 44 years (range=28-80).

The median duration of drainage maintenance was almost equivalent: 2.1 days (range=2-3 days) in the PRP group and 2.4 days (range=1-3 days) in not PRP group (p-value not statistically significant).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Parameters evaluated during follow-up.

As reported in Table I, median serum drainage was 15 cc (range: 5-50 cc) in the PRP-group, and 22.5 cc (range: 10-340 cc) in the not-PRP-group (the difference was not statistically significant). Patients from both groups were discharged after a median of two days of hospitalization (range=2-4 days).

None of PRP-treated patients reported any transient facial nerve deficit, whereas two cases not treated with PRP presented compromised facial nerve function.

Frey's syndrome was diagnosed in four out of eight PRP-treated patients and in nine out of twelve patients not treated with PRP.

No patient developed recurrence in the postoperative period. Only one patient developed a second tumor.

A thorough evaluation of the facial muscles was performed during the postoperative period and follow-up, recording for each one of the days needed to recover full functionality. Table II reports the average amount of time for muscle recovering in the PRP and no PRP groups.

For each measured clinical parameter, we performed a t-test (16). The p-value for each parameter is reported in Table III. Parameters that were significantly different (p-value <0.1) across the two sets of patients were keloids/depression, cosmetic result, great auricular nerve conservation and Frey's syndrome. For all the parameters above, PRP gel application had a positive effect when applied.

Discussion

Our explorative analysis on PRP gel application in patients undergoing parotidectomy suggests a positive effect of PRP on surgical outcome, with no negative effects detected. In fact, some parameters measured during follow-up were significantly improved in patients to whom gel was applied as compared patients to whom it was not (Table III).

PRP is a valid choice for the treatment of Frey's syndrome and an alternative to treatment with Botulin toxin type A, as reported in literature (17). Furthermore, facial nerve function was conserved in all patients treated with PRP gel, whereas two patients not treated with PRP presented a significant deficit.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Average days required for recovery of each muscle.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Significantly improved parameters in the group treated with PRP gel.

We must note our small sample size, as well as the categorical nature of the collected data that could have affected statistical analysis. Nonetheless, our study is meant to be an explorative analysis, in order to evaluate the possibility of carrying out a large-size clinical trial with a better experimental design.

Indeed this work highlights the positive effect of PRP on patients undergoing parotidectomy, and indicates that more effort has to be put on the study of the effect of PRP gel.

Footnotes

  • Disclosure

    Marco Scala, Paola Mereu, Francesco Spagnolo, Michela Massa, Annalisa Barla, Sofia Mosci, Gilberto Forno, Andra Ingenito and Paolo Strada have no financial interest in any of the products, devices, or drugs mentioned in this article.

  • Received September 24, 2013.
  • Revision received November 27, 2013.
  • Accepted November 28, 2013.
  • Copyright © 2014 The Author(s). Published by the International Institute of Anticancer Research.

References

  1. ↵
    1. Batsakis JG
    : Tumors of the major salivary glands. In: Tumors of the Head and Neck: Clinical and Pathological Considerations. New York: Williams & Wilkins. pp. 1-37, 2000.
  2. ↵
    1. Ascani G,
    2. Pieramici T,
    3. Messi M,
    4. Lupi E,
    5. Rubini C,
    6. Balercia P
    : Salivary gland tumours: A retrospective study of 454 patients. Minerva Stomatol 55: 209-214, 2006.
    OpenUrlPubMed
  3. ↵
    1. Lima SS,
    2. Soares AF,
    3. Amorim RF,
    4. Freitas RD
    : Epidemiologic profile of salivary gland neoplasms: Analysis of 245 cases. Rev Bras Otorrinolaringol 71: 335-340, 2005.
    OpenUrl
  4. ↵
    1. Machtens E
    : Salivary gland diseases. Mund Kiefer Gesichtschir 4(Suppl 1): S401-S413, 2000 (in German).
    OpenUrlPubMed
  5. ↵
    1. Zernial O,
    2. Springer IN,
    3. Warnke P,
    4. Härle F,
    5. Risick C,
    6. Wiltfang J
    : Long-term recurrence rate of pleomorphic adenoma and postoperative facial nerve paresis (in parotid surgery). J Craniomaxillofac Surg 35(3): 189-192, 2007.
    OpenUrlPubMed
  6. ↵
    1. Beurskens CH,
    2. Heymans PG
    : Physiotherapy in patients with facial nerve paresis: Description of outcomes. Am J Otolaryngol 25: 394-400, 2004.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gaillard C,
    2. Perie S,
    3. Susini B,
    4. St Guily JL
    : Facial nerve dysfunction after parotidectomy: The role of local factors. Laryngoscope 115: 287-291, 2005.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Yu GY
    . Superficial parotidectomy through retrograde facial nerve dissection. JR Coll Surg Edinb 46(2): 104-107, 2001.
    OpenUrl
  9. ↵
    1. Sariguney Y,
    2. Yavuzer R,
    3. Elmas C,
    4. Yenicesu I,
    5. Bolay H,
    6. Atabay K
    : Effect of platelet-rich plasma on peripheral nerve regeneration. J Reconstr Microsurg 24(3): 159-167, 2008.
    OpenUrlPubMed
  10. ↵
    1. Jurk K,
    2. Kehrel BE
    : Platelets: physiology and biochemistry. Semin Thromb Hemost 31: 381-392, 2005.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Eppley BL,
    2. Woodell JE,
    3. Higgins J
    : Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg 114(6): 1502-1508, 2004.
    OpenUrlPubMed
  12. ↵
    1. Krasna M,
    2. Domanović D,
    3. Tomsic A,
    4. Svajger U,
    5. Jeras M
    : Platelet gel stimulates proliferation of human dermal fibroblasts in vitro. Acta Dermatovenerol Alp Panonica Adriat 16(3): 105-110, 2007.
    OpenUrlPubMed
  13. ↵
    1. Krupski WC,
    2. Reilly LM,
    3. Perez S,
    4. Moss KM,
    5. Crombleholme PA,
    6. Rapp JH
    : A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic non healing wounds: A preliminary report. J Vasc Surg 14: 526-532, 1991.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Marx RE,
    2. Carlson ER,
    3. Eichstaedt RM,
    4. Schimmele SR,
    5. Strauss JE,
    6. Georgeff KR
    : Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85(6): 638-646, 1998.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Cenni E,
    2. Savarino L,
    3. Perut F,
    4. Fotia C,
    5. Avnet S,
    6. Sabbioni G
    : Background and rationale of platelet gel in orthopaedic surgery. Musculoskelet Surg 94(1): 1-8, 2010.
    OpenUrlPubMed
  16. ↵
    1. Snedecor GW,
    2. Cochran WG
    : Statistical Methods. Iowa State University Press, 1989.
  17. ↵
    1. Luna Ortiz K,
    2. Rascon Ortiz M,
    3. Sansón Riofrio JA,
    4. Villavicencio Valencia V,
    5. Mosqueda Taylor A
    : Control of Frey's syndrome in patients treated with botulinum toxin type A. Med Oral Patol Oral Cir Bucal 12(1): E79-84, 2007.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

In Vivo
Vol. 28, Issue 1
January-February 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study
MARCO SCALA, PAOLA MEREU, FRANCESCO SPAGNOLO, MICHELA MASSA, ANNALISA BARLA, SOFIA MOSCI, GILBERTO FORNO, ANDRA INGENITO, PAOLO STRADA
In Vivo Jan 2014, 28 (1) 121-124;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study
MARCO SCALA, PAOLA MEREU, FRANCESCO SPAGNOLO, MICHELA MASSA, ANNALISA BARLA, SOFIA MOSCI, GILBERTO FORNO, ANDRA INGENITO, PAOLO STRADA
In Vivo Jan 2014, 28 (1) 121-124;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer
  • Google Scholar

More in this TOC Section

  • Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS
  • Expression Patterns of T-cell immunoreceptor With Ig and ITIM domains (TIGIT) in Classical Hodgkin Lymphoma: A Clinicopathological Study
  • Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder Cancer
Show more Clinical Studies

Keywords

  • regenerative medicine
  • platelet-rich plasma
  • platelet gel
  • parotidectomy
  • salivary gland tumors
In Vivo

© 2026 In Vivo

Powered by HighWire